Biogen Inc. $BIIB Shares Acquired by Hills Bank & Trust Co

Hills Bank & Trust Co lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 17.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,586 shares of the biotechnology company’s stock after acquiring an additional 829 shares during the period. Hills Bank & Trust Co’s holdings in Biogen were worth $702,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Greykasell Wealth Strategies Inc. acquired a new stake in shares of Biogen during the first quarter valued at $27,000. Vision Financial Markets LLC acquired a new stake in shares of Biogen during the first quarter valued at $27,000. Zions Bancorporation National Association UT acquired a new stake in shares of Biogen during the first quarter valued at $29,000. Concord Wealth Partners boosted its stake in shares of Biogen by 100.0% during the second quarter. Concord Wealth Partners now owns 228 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 114 shares during the last quarter. Finally, Private Trust Co. NA boosted its stake in shares of Biogen by 74.8% during the first quarter. Private Trust Co. NA now owns 229 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 98 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. BMO Capital Markets increased their price objective on Biogen from $128.00 to $150.00 in a research note on Friday. Piper Sandler increased their price objective on Biogen from $115.00 to $118.00 and gave the company a “neutral” rating in a research note on Friday, September 12th. Citigroup reissued a “neutral” rating on shares of Biogen in a research note on Wednesday, September 24th. Robert W. Baird decreased their price target on Biogen from $255.00 to $250.00 in a research note on Friday. Finally, Jefferies Financial Group began coverage on Biogen in a research note on Thursday, September 25th. They issued a “buy” rating and a $190.00 price target on the stock. Nine research analysts have rated the stock with a Buy rating and nineteen have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $177.00.

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 517 shares of Biogen stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $133.55, for a total value of $69,045.35. Following the transaction, the insider directly owned 5,772 shares of the company’s stock, valued at $770,850.60. The trade was a 8.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.18% of the stock is owned by corporate insiders.

Biogen Stock Up 3.1%

Shares of NASDAQ:BIIB opened at $154.27 on Friday. The firm has a market cap of $22.62 billion, a price-to-earnings ratio of 14.75, a PEG ratio of 1.17 and a beta of 0.13. Biogen Inc. has a 12-month low of $110.04 and a 12-month high of $179.48. The company has a current ratio of 2.50, a quick ratio of 1.79 and a debt-to-equity ratio of 0.36. The stock’s 50-day moving average price is $144.21 and its two-hundred day moving average price is $133.65.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Thursday, October 30th. The biotechnology company reported $4.81 earnings per share for the quarter, beating the consensus estimate of $3.89 by $0.92. The business had revenue of $2.53 billion for the quarter, compared to analyst estimates of $2.34 billion. Biogen had a return on equity of 13.85% and a net margin of 15.31%.The company’s revenue was up 2.8% compared to the same quarter last year. During the same period in the previous year, the company posted $4.08 EPS. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS. On average, research analysts forecast that Biogen Inc. will post 15.83 EPS for the current year.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.